TWI256309B - New formulation of mirtazapine - Google Patents

New formulation of mirtazapine

Info

Publication number
TWI256309B
TWI256309B TW089119264A TW89119264A TWI256309B TW I256309 B TWI256309 B TW I256309B TW 089119264 A TW089119264 A TW 089119264A TW 89119264 A TW89119264 A TW 89119264A TW I256309 B TWI256309 B TW I256309B
Authority
TW
Taiwan
Prior art keywords
mirtazapine
dosage unit
effects
new formulation
new
Prior art date
Application number
TW089119264A
Other languages
English (en)
Inventor
Nijs Henrik De
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240737&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI256309(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of TWI256309B publication Critical patent/TWI256309B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW089119264A 1999-10-13 2000-09-19 New formulation of mirtazapine TWI256309B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203338 1999-10-13

Publications (1)

Publication Number Publication Date
TWI256309B true TWI256309B (en) 2006-06-11

Family

ID=8240737

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089119264A TWI256309B (en) 1999-10-13 2000-09-19 New formulation of mirtazapine

Country Status (28)

Country Link
EP (1) EP1223914B1 (zh)
JP (1) JP5561885B2 (zh)
KR (1) KR100708560B1 (zh)
CN (1) CN1173701C (zh)
AR (1) AR026010A1 (zh)
AT (1) ATE274899T1 (zh)
AU (1) AU780379B2 (zh)
BR (1) BR0014593A (zh)
CA (1) CA2386547C (zh)
CO (1) CO5251412A1 (zh)
CZ (1) CZ20021315A3 (zh)
DE (2) DE1223914T1 (zh)
ES (1) ES2194618T3 (zh)
HK (1) HK1046641B (zh)
HU (1) HUP0203148A3 (zh)
IL (2) IL148777A0 (zh)
MX (1) MXPA02003519A (zh)
NO (1) NO20021730L (zh)
NZ (1) NZ518165A (zh)
PE (1) PE20010699A1 (zh)
PL (1) PL200858B1 (zh)
PT (1) PT1223914E (zh)
RU (1) RU2261098C2 (zh)
SK (1) SK6452002A3 (zh)
TR (1) TR200200978T2 (zh)
TW (1) TWI256309B (zh)
WO (1) WO2001026621A2 (zh)
ZA (1) ZA200202293B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051349A2 (en) * 2003-11-25 2005-06-09 Aurobindo Pharma Ltd. Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
EP2001495A4 (en) * 2006-02-27 2010-12-08 Alexander Michalow METHODS OF REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATION
CN101129341B (zh) * 2006-08-22 2011-06-01 上海医药工业研究院 口内崩解组合物及其制备方法
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN102993208B (zh) * 2011-11-22 2017-01-18 北京哈三联科技股份有限公司 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用
AR090218A1 (es) * 2012-03-02 2014-10-29 Rhodes Pharmaceuticals Lp Formulaciones de liberacion inmediata resistentes a la manipulacion
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
DK3261645T3 (da) 2015-02-27 2021-06-07 Dechra Ltd Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte
JP6601844B2 (ja) * 2016-12-05 2019-11-06 共和薬品工業株式会社 光安定性に優れたミルタザピン含有医薬製剤
CN111714463B (zh) * 2020-08-14 2022-06-17 华农（肇庆）生物产业技术研究院有限公司 米氮平口服剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
EP0737473A1 (en) * 1989-10-02 1996-10-16 Cima Labs, Inc. Effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
JPH0436252A (ja) * 1990-05-30 1992-02-06 Nippon Alkyl Alum Kk 光学活性アルキニルアルコールの製造方法
JP3168695B2 (ja) * 1991-06-14 2001-05-21 三菱化学株式会社 ショ糖脂肪酸エステルの置換度の低下方法
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH05163137A (ja) * 1991-12-12 1993-06-29 Shin Etsu Chem Co Ltd 有核顆粒
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JPH0737473A (ja) * 1993-07-27 1995-02-07 Murata Mfg Co Ltd 圧力スイッチ
JPH10139659A (ja) * 1996-09-10 1998-05-26 Freunt Ind Co Ltd 球形粒子群、その製造方法及びそれを用いた球形粒子製剤
JP3870470B2 (ja) * 1997-02-07 2007-01-17 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤

Also Published As

Publication number Publication date
IL148777A0 (en) 2002-09-12
WO2001026621A3 (en) 2001-10-11
DE1223914T1 (de) 2003-09-18
CA2386547A1 (en) 2001-04-19
HK1046641B (zh) 2005-04-08
WO2001026621A2 (en) 2001-04-19
HK1046641A1 (en) 2003-01-24
EP1223914B1 (en) 2004-09-01
AU1023201A (en) 2001-04-23
RU2002112238A (ru) 2004-01-10
TR200200978T2 (tr) 2002-09-23
MXPA02003519A (es) 2002-08-20
DE60013466D1 (de) 2004-10-07
KR100708560B1 (ko) 2007-04-19
PL200858B1 (pl) 2009-02-27
JP2003511403A (ja) 2003-03-25
SK6452002A3 (en) 2002-09-10
NZ518165A (en) 2004-03-26
CO5251412A1 (es) 2003-02-28
DE60013466T2 (de) 2005-01-20
ES2194618T1 (es) 2003-12-01
CN1378452A (zh) 2002-11-06
CN1173701C (zh) 2004-11-03
HUP0203148A2 (hu) 2003-01-28
BR0014593A (pt) 2002-06-11
AR026010A1 (es) 2002-12-26
HUP0203148A3 (en) 2004-06-28
NO20021730D0 (no) 2002-04-12
KR20020038946A (ko) 2002-05-24
ATE274899T1 (de) 2004-09-15
AU780379B2 (en) 2005-03-17
JP5561885B2 (ja) 2014-07-30
CA2386547C (en) 2010-06-08
IL148777A (en) 2013-10-31
PE20010699A1 (es) 2001-07-06
RU2261098C2 (ru) 2005-09-27
CZ20021315A3 (cs) 2002-07-17
ZA200202293B (en) 2003-06-20
EP1223914A2 (en) 2002-07-24
PT1223914E (pt) 2004-11-30
PL354584A1 (en) 2004-01-26
NO20021730L (no) 2002-05-30
ES2194618T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY119403A (en) Novel compounds with analgesic effect.
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
HUP0301121A2 (hu) Külsżleges gyógyszerkészítmények és gyógykezelések
AP2001002264A0 (en) Sustained release formulations for growth hormone secretagogues.
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
TR200002207T1 (tr) Slekoksib bileşikleri.
PL350313A1 (en) Apomorphine and sildenafil composition
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
TWI256309B (en) New formulation of mirtazapine
SE9900961D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
IL152328A (en) Preparations containing a combination of defibrotide and one or more hematopoietic factors and their use
SE9802209D0 (sv) Novel compounds
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
GB0018322D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent